ScholarLens Back to search
2015•Journal of VirologyOpen access

Development of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine

Andrew Cox, Steven F. Baker, Aitor Nogales, Luis Martínez‐Sobrido, Stephen Dewhurst

Open full text 39 citations

Abstract

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

Open-access reader

About this research paper

What this paper is about

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

Why it matters

OpenAlex reports 39 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

Key concepts: Live attenuated influenza vaccine, Virology, Attenuated vaccine, In vivo, Biology, Virus, Lethality, Influenza A virus

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Development of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine — Research Paper | ScholarLens